EC50 of propofol with target controlled infusion for intrathecal injection of Nusinersen in children with spinal muscular atrophy

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200063672

Enrollment

Unknown

Registered

2022-09-14

Start date

2022-09-14

Completion date

Unknown

Last updated

2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal muscular atrophy

Interventions

none:Target controlled infusion of propofol for intravenous anesthesia

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: (1) sedation and anesthesia were needed; (2) no obvious abnormality in liver and kidney function and biochemical indicators, no history of myocardial infarction and cerebrovascular accident; (3) no contraindications to lumbar puncture such as puncture site infection; (4) family members or guardian signed the informed consent. (5) ASA grades were grades I to II.

Exclusion criteria

Exclusion criteria: Exclusion criteria: (1) had a history of allergies related to sedatives and anesthetics; (2) SMA type I; (3) abnormal coagulation function; (4) needed breathing support such as oxygen inhalation; (5) full stomach patient or had intestinal obstruction and gastric retention.

Design outcomes

Primary

Measure	Time frame
Sedation onset time;recovery time;dose of propofol;Cp;Cpt;MAP;HR;SpO2;RR;PETCO2;BIS;	—

Secondary

Measure	Time frame
adverse reactions.;postoperative follow-up.;	—

Countries

China

Contacts

Public ContactLanying Lin

linlanying@163.com+86 13859089869

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026